

Thomas P Lodise

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4660011/publications.pdf>

Version: 2024-02-01

202
papers

9,140
citations

61984

43
h-index

45317

90
g-index

207
all docs

207
docs citations

207
times ranked

6488
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 825-864.	1.0	640
2	Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2003, 36, 1418-1423.	5.8	546
3	Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1330-1336.	3.2	519
4	Relationship between Initial Vancomycin Concentrationâ€Time Profile and Nephrotoxicity among Hospitalized Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 507-514.	5.8	501
5	Piperacillin-Tazobactam for <i>Pseudomonas aeruginosa</i> Infection: Clinical Implications of an Extended-Infusion Dosing Strategy. <i>Clinical Infectious Diseases</i> , 2007, 44, 357-363.	5.8	489
6	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 226-240.	9.1	411
7	Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 309-316.	3.2	314
8	Predictors of 30-Day Mortality among Patients with <i>Pseudomonas aeruginosa</i> Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3510-3515.	3.2	279
9	Innovative approaches to optimizing the delivery of vancomycin in individual patients. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 50-57.	13.7	215
10	Vancomycin: We Can't Get There From Here. <i>Clinical Infectious Diseases</i> , 2011, 52, 969-974.	5.8	214
11	Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on β -Lactam Antibiotics: Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2006, 26, 1320-1332.	2.6	210
12	Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2018, 46, 12-20.	0.9	183
13	Clinical and economic impact of methicillin resistance in patients with <i>Staphylococcus aureus</i> bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 113-122.	1.8	175
14	A Systematic Review of the Methods Used to Assess the Association between Appropriate Antibiotic Therapy and Mortality in Bacteremic Patients. <i>Clinical Infectious Diseases</i> , 2007, 45, 329-337.	5.8	173
15	Considerations for the Use of Phage Therapy in Clinical Practice. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0207121.	3.2	151
16	Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy150.	0.9	143
17	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2020, 71, 1361-1364.	5.8	142
18	Vancomycin Exposure in Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections: How Much Is Enough?. <i>Clinical Infectious Diseases</i> , 2014, 59, 666-675.	5.8	139

#	ARTICLE	IF	CITATIONS
19	Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 864-871.	3.2	128
20	Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4718-4724.	3.2	109
21	The Emperor's New Clothes: Prospective Observational Evaluation of the Association Between Initial Vancomycin Exposure and Failure Rates Among Adult Hospitalized Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). <i>Clinical Infectious Diseases</i> , 2020, 70, 1536-1545.	5.8	106
22	Comparison of β -Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3977-3982.	3.2	101
23	Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3731-3733.	3.2	92
24	Burden of Methicillin-Resistant Staphylococcus aureus: Focus on Clinical and Economic Outcomes. <i>Pharmacotherapy</i> , 2007, 27, 1001-1012.	2.6	74
25	Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections. <i>American Journal of the Medical Sciences</i> , 2019, 357, 103-110.	1.1	69
26	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4252-4259.	3.2	68
27	Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2978-2985.	3.2	68
28	Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2300-2304.	3.2	65
29	Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3294-3301.	3.2	64
30	Platelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7198-7204.	3.2	63
31	Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5742-5751.	3.2	61
32	Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC ≤ 1 mg/L: A Multicenter Evaluation. <i>Clinical Therapeutics</i> , 2016, 38, 16-30.	2.5	60
33	Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1600-1608.	3.0	59
34	Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. <i>Pharmacotherapy</i> , 2018, 38, 1229-1238.	2.6	59
35	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo- β -Lactamase-1. <i>Clinical Infectious Diseases</i> , 2020, 71, 1095-1098.	5.8	59
36	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2020, 40, 363-367.	2.6	56

#	ARTICLE	IF	CITATIONS
37	Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106344.	2.5	54
38	Fluoroquinolone and Third-Generation-Cephalosporin Resistance among Hospitalized Patients with Urinary Tract Infections Due to <i>Escherichia coli</i> : Do Rates Vary by Hospital Characteristics and Geographic Region?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3170-3173.	3.2	53
39	Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?. <i>Pharmacotherapy</i> , 2016, 36, 679-693.	2.6	53
40	Clinical Prediction Tool To Identify Patients with <i>Pseudomonas aeruginosa</i> Respiratory Tract Infections at Greatest Risk for Multidrug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 417-422.	3.2	51
41	Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5507-5511.	3.2	51
42	Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2017, 64, S24-S29.	5.8	48
43	Use of Pharmacokinetic/Pharmacodynamic Systems Analyses to Inform Dose Selection of Tedizolid Phosphate. <i>Clinical Infectious Diseases</i> , 2014, 58, S28-S34.	5.8	47
44	Pharmacokinetics and Pharmacodynamics: Optimal Antimicrobial Therapy in the Intensive Care Unit. <i>Critical Care Clinics</i> , 2011, 27, 1-18.	2.6	46
45	Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	46
46	Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 45-52.	1.8	43
47	Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections. <i>Drugs</i> , 2012, 72, 1473-1493.	10.9	43
48	Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1228-1236.	3.0	43
49	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2326-2334.	3.0	41
50	A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to <i>Klebsiella pneumoniae</i> or <i>Escherichia coli</i> : how long is too long?. <i>BMC Infectious Diseases</i> , 2018, 18, 625.	2.9	40
51	Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2553-2558.	3.0	39
52	Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 266-275.	1.8	39
53	24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	39
54	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2622-2632.	3.0	39

#	ARTICLE	IF	CITATIONS
55	Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 494-502.	3.0	38
56	Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2285-2290.	3.0	35
57	Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 239-259.	1.8	34
58	Evaluation of Once-Daily Vancomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 682-686.	3.2	33
59	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 261-264.	1.3	33
60	Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations. <i>Clinical Therapeutics</i> , 2016, 38, 136-148.	2.5	32
61	Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to <i>Pseudomonas aeruginosa</i> with MIC values between 4 and 32 µg/L. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2813-2816.	3.0	32
62	Pharmacokinetic and pharmacodynamic profile of ceftobiprole. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 96-102.	1.8	30
63	A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	30
64	Using Therapeutic Drug Monitoring to Treat KPC-Producing <i>Klebsiella pneumoniae</i> Central Nervous System Infection With Ceftazidime/Avibactam. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa349.	0.9	30
65	Hospital admission patterns in adult patients with skin and soft tissue infections: Identification of potentially avoidable hospital admissions through a retrospective database analysis. <i>Hospital Practice (1995)</i> , 2015, 43, 137-143.	1.0	29
66	Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz194.	0.9	29
67	Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 223-230.	1.8	28
68	Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1081-1088.	4.5	27
69	Safety of Delafloxacin: Focus on Adverse Events of Special Interest. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy220.	0.9	27
70	Vancomycin Area Under the Curve—Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: Putting the Safety of Our Patients First. <i>Clinical Infectious Diseases</i> , 2021, 72, 1497-1501.	5.8	27
71	All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 707-719.	4.4	27
72	Approach to the Treatment of Patients with Serious Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections. <i>Pharmacotherapy</i> , 2020, 40, 952-969.	2.6	26

#	ARTICLE	IF	CITATIONS
73	A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 727-735.	3.0	25
74	Identification of Patients With <i>Pseudomonas aeruginosa</i> Respiratory Tract Infections at Greatest Risk of Infection With Carbapenem-Resistant Isolates. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 959-965.	1.8	24
75	Use of pharmacodynamic principles to inform β -lactam dosing: β -lactams does not always mean success. <i>Journal of Hospital Medicine</i> , 2011, 6, S16-23.	1.4	24
76	Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
77	Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections. <i>BMC Infectious Diseases</i> , 2019, 19, 718.	2.9	24
78	Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1945-1951.	3.2	23
79	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <i>Infectious Diseases and Therapy</i> , 2020, 9, 561-572.	4.0	23
80	Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy297.	0.9	22
81	Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings. <i>Pharmacotherapy</i> , 2018, 38, 1205-1215.	2.6	22
82	Treatment of patients with serious infections due to carbapenem-resistant <i>Acinetobacter baumannii</i> : How viable are the current options?. <i>Pharmacotherapy</i> , 2021, 41, 762-780.	2.6	22
83	Effects of Gatifloxacin and Levofloxacin on Rates of Hypoglycemia and Hyperglycemia Among Elderly Hospitalized Patients. <i>Pharmacotherapy</i> , 2007, 27, 1498-1505.	2.6	21
84	Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3804-3813.	3.2	21
85	Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw274.	0.9	20
86	Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 239-243.	2.5	20
87	Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 176-179.	3.0	19
88	Assessment of Time to Clinical Response, a Proxy for Discharge Readiness, among Hospitalized Patients with Community-Acquired Pneumonia Who Received either Ceftaroline Fosamil or Ceftriaxone in Two Phase III FOCUS Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1119-1126.	3.2	19
89	Development and Assessment of Risk Scores for Carbapenem and Extensive β -Lactam Resistance Among Adult Hospitalized Patients With <i>Pseudomonas aeruginosa</i> Infection. <i>JAMA Network Open</i> , 2018, 1, e183927.	5.9	19
90	Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	19

#	ARTICLE	IF	CITATIONS
91	Dalbavancin as an option for treatment of <i>S. aureus</i> bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. <i>Trials</i> , 2022, 23, 407.	1.6	19
92	Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 877-881.	3.0	17
93	Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. <i>Clinical Drug Investigation</i> , 2016, 36, 157-168.	2.2	17
94	Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE. <i>Infectious Diseases and Therapy</i> , 2014, 3, 123-132.	4.0	16
95	An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. <i>BMC Infectious Diseases</i> , 2015, 15, 503.	2.9	16
96	Prevalence of Invasive Infections Due to Carbapenem-Resistant Enterobacteriaceae among Adult Patients in U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	16
97	A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults. <i>Pharmacotherapy</i> , 2018, 38, 981-985.	2.6	16
98	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 233-240.	2.5	15
99	Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline. <i>Pharmacotherapy</i> , 2021, 41, 915-931.	2.6	15
100	Relationship between Various Definitions of Prior Antibiotic Exposure and Piperacillin-Tazobactam Resistance among Patients with Respiratory Tract Infections Caused by <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2933-2936.	3.2	14
101	Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2014, 3, 225-233.	4.0	14
102	Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 752-764.	0.9	14
103	Ertapenem Pharmacokinetics and Pharmacodynamics during Continuous Ambulatory Peritoneal Dialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 725-730.	3.2	13
104	Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class. <i>Antibiotics</i> , 2020, 9, 905.	3.7	13
105	The Pharmacodynamic-Toxicodynamic Relationship of AUC and C_{max} in Vancomycin-Induced Kidney Injury in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	13
106	New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	13
107	Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections. <i>BMC Infectious Diseases</i> , 2017, 17, 176.	2.9	12
108	Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Drug Investigation</i> , 2018, 38, 935-943.	2.2	12

#	ARTICLE	IF	CITATIONS
109	Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0106021.	3.2	12
110	A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
111	Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
112	The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies. <i>Drugs - Real World Outcomes</i> , 2020, 7, 6-12.	1.6	11
113	Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 359-367.	2.4	10
114	Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated with Complicated Urinary Tract Infection. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	10
115	Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway. <i>Drugs - Real World Outcomes</i> , 2020, 7, 30-35.	1.6	9
116	Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable?. <i>American Journal of Infection Control</i> , 2021, 49, 1528-1534.	2.3	9
117	Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin-resistant <i>Staphylococcus aureus</i> : a pooled data analysis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 295-301.	1.8	8
118	Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz475.	0.9	8
119	Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	8
120	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) by Etest [®] macromethod among patients with MRSA bloodstream infections: a pilot study. <i>BMC Infectious Diseases</i> , 2017, 17, 534.	2.9	7
121	Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant <i>Staphylococcus aureus</i> Complicated Skin and Soft Tissue Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, e4560-e4567.	5.8	7
122	Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. <i>Frontiers in Medicine</i> , 2020, 7, 585658.	2.6	7
123	Validity of 2020 vancomycin consensus recommendations and further guidance for practical application. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1364-1367.	1.0	7
124	The case for precision dosing: medical conservatism does not justify inaction. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1661-1665.	3.0	7
125	Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. <i>American Health and Drug Benefits</i> , 2018, 11, 449-459.	0.5	7
126	Vancomycin plus Piperacillin/Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	6

#	ARTICLE	IF	CITATIONS
127	The Emperor's New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). <i>Open Forum Infectious Diseases</i> , 2017, 4, S30-S31.	0.9	6
128	Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by <i>Staphylococcus aureus</i> . <i>Clinical Therapeutics</i> , 2018, 40, 406-414.e2.	2.5	6
129	Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis. <i>Drugs - Real World Outcomes</i> , 2020, 7, 20-29.	1.6	6
130	Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa145.	0.9	6
131	Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting. <i>Infectious Diseases and Therapy</i> , 2020, 9, 107-117.	4.0	6
132	Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab651.	0.9	6
133	Determination of plasma protein binding of dalbavancin. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1899-1902.	3.0	6
134	Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters". <i>Pharmacotherapy</i> , 2020, 40, 889-901.	2.6	5
135	COVID-19: Important Therapy Considerations and Approaches in this Hour of Need. <i>Pharmacotherapy</i> , 2020, 40, 379-381.	2.6	5
136	Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to <i>Clostridioides difficile</i> . <i>Pharmacotherapy</i> , 2021, 41, 212-219.	2.6	5
137	Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective. <i>American Health and Drug Benefits</i> , 2019, 12, S1-S12.	0.5	5
138	The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1131-1133.	2.0	4
139	An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa237.	0.9	4
140	Intravenous Compatibility of Ceftazidime-Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. <i>Clinical Therapeutics</i> , 2020, 42, 1580-1586.e2.	2.5	4
141	Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa209.	0.9	4
142	Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals. <i>Antibiotics</i> , 2020, 9, 577.	3.7	4
143	In vitro activity of imipenem/relebactam plus aztreonam against metallo- β -lactamase-producing, OprD-deficient <i>Pseudomonas aeruginosa</i> with varying levels of <i>Pseudomonas</i> -derived cephalosporinase production. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106595.	2.5	4
144	Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1873-1876.	3.0	3

#	ARTICLE	IF	CITATIONS
145	1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015. <i>Open Forum Infectious Diseases</i> , 2018, 5, S360-S360.	0.9	3
146	Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. <i>Infectious Diseases and Therapy</i> , 2020, 9, 953-966.	4.0	3
147	Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions among Hospitalized Veterans Affairs Patients with Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
148	Outcomes of adult patients in the intensive care unit with <i>Pseudomonas aeruginosa</i> pneumonia who received an active anti-pseudomonal β -lactam: Does β -S β -equal success in the presence of 2.6 resistance to other anti-pseudomonal β -lactams?. <i>Pharmacotherapy</i> , 2021, 41, 658-667.	2.6	3
149	US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab380.	0.9	3
150	A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. <i>Journal of Medical Microbiology</i> , 2020, 69, 625-630.	1.8	3
151	Vancomycin Area Under the Curve—guided Dosing and Monitoring: β els the Juice Worth the Squeeze β ?. <i>Pharmacotherapy</i> , 2020, 40, 1176-1179.	2.6	3
152	Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections. <i>American Health and Drug Benefits</i> , 2019, 12, S13-S24.	0.5	3
153	Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 193-197.	1.8	2
154	Clinical and Economic Burden of Multi-drug Resistant <i>Pseudomonas</i> sp. (MDRP) Among Patients With Serious Infections in United States Hospitals. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	2
155	Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?. <i>Open Forum Infectious Diseases</i> , 2017, 4, S283-S284.	0.9	2
156	Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?. <i>Open Forum Infectious Diseases</i> , 2017, 4, S14-S14.	0.9	2
157	Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 126-129.	3.0	2
158	The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model. <i>Clinical Drug Investigation</i> , 2020, 40, 961-971.	2.2	2
159	In vivo studies on antibiotic combination for the treatment of carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis protocol. <i>BMI Open Science</i> , 2020, 44, e100055.	1.7	2
160	Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of <i>Clostridioides difficile</i> Infection. <i>Clinical Drug Investigation</i> , 2021, 41, 269-275.	2.2	2
161	Hospital Readmissions and Mortality Among Intubated and Mechanically Ventilated Adult Subjects With Pneumonia Due to Gram-Negative Bacteria. <i>Respiratory Care</i> , 2021, 66, 742-750.	1.6	2
162	Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcyclohexane Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models. <i>American Health and Drug Benefits</i> , 2019, 12, 168-176.	0.5	2

#	ARTICLE	IF	CITATIONS
163	1041 Economic Burden Associated with Key Gram-negative Pathogens among Patients with Complicated Urinary Tract Infections across US Hospitals. <i>Open Forum Infectious Diseases</i> , 2014, 1, S305-S305.	0.9	1
164	Use of PK/PD Systems Analyses to Determine the Optimal Fixed Dosing Regimen of Iclaprim (ICL) for Phase III ABSSSI Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
165	Identification of Patients at Greatest Risk for Carbapenem Resistance in Patients With Serious Hospital-Onset Infections Due to Enterobacteriaceae Species. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
166	Association Between Carbapenem Resistance and Mortality Among Adults Hospitalized With Serious Infections Due to an Enterobacteriaceae spp: Results of a Systematic Literature Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
167	Determination of Alternative Ceftolozane/Tazobactam (C/T) Dosing Regimens for Patients With Infections Due to <i>Pseudomonas aeruginosa</i> With High (C/T) MIC Values. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
168	Does Timing of Receipt of Appropriate Antimicrobial Therapy Make a Difference Among Patients With Serious Infections Due to Resistant Gram-Negative Pathogens?. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
169	Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. <i>Surgical Infections</i> , 2016, 17, 675-682.	1.4	1
170	1385. Efficacy of Ceftazidime+Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-Lactamase Producing-Enterobacteriaceae (MBL). <i>Open Forum Infectious Diseases</i> , 2018, 5, S425-S425.	0.9	1
171	676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2). <i>Open Forum Infectious Diseases</i> , 2019, 6, S308-S309.	0.9	1
172	Myelosuppression with Oxazolidinones: Are There Differences?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	1
173	Questions on Vancomycin Dosing. <i>Clinical Infectious Diseases</i> , 2020, 73, e1777-e1778.	5.8	1
174	Managing Bacterial Infections in the Era of COVID-19. <i>Infectious Diseases in Clinical Practice</i> , 2020, 28, 251-254.	0.3	1
175	Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for <i>Clostridioides difficile</i> Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. <i>Antibiotics</i> , 2021, 10, 1195.	3.7	1
176	1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US). <i>Open Forum Infectious Diseases</i> , 2020, 7, S822-S822.	0.9	1
177	The 30-Day Economic Burden of Newly Diagnosed Complicated Urinary Tract Infections in Medicare Fee-for-Service Patients Who Resided in the Community. <i>Antibiotics</i> , 2022, 11, 578.	3.7	1
178	Reply to Tucker and Wu. <i>Clinical Infectious Diseases</i> , 2007, 45, 269-270.	5.8	0
179	Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection. , 2012, , 175-196.		0
180	1031 Comparative Epidemiology of Complicated Urinary Tract Infections (cUTI) by Age among US Hospitals. <i>Open Forum Infectious Diseases</i> , 2014, 1, S302-S302.	0.9	0

#	ARTICLE	IF	CITATIONS
181	Telavancin Versus Vancomycin in the Treatment of Hospital-Acquired Pneumonia Caused by Staphylococcus aureus: Decision Analytic Model. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
182	1338. A Pooled Analysis of Patients With Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to Evaluate the Safety and Efficacy of Iclaprim Vs. Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections. Open Forum Infectious Diseases, 2018, 5, S409-S409.	0.9	0
183	1419. 24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. Open Forum Infectious Diseases, 2018, 5, S437-S438.	0.9	0
184	2414. Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated With Ceftolozane/Tazobactam Across 253 US Hospitals. Open Forum Infectious Diseases, 2018, 5, S722-S722.	0.9	0
185	1237. New York State Outpatient Regional Antibigram for Urinary Pathogens: Have We Reached a Post Antibiotic Era for the Treatment of UTIs?. Open Forum Infectious Diseases, 2018, 5, S376-S376.	0.9	0
186	1463. Comparative Evaluation of Adverse Tendon Events Between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin Among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia. Open Forum Infectious Diseases, 2018, 5, S452-S453.	0.9	0
187	681. Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States Hospitals, 2010â€“2015. Open Forum Infectious Diseases, 2018, 5, S245-S246.	0.9	0
188	1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillinâ€“Tazobactam. Open Forum Infectious Diseases, 2019, 6, S483-S483.	0.9	0
189	1440. Prevalence and Regional Variation of in ESBLs and CRE Enterobacteriaceae (ENT) among Adult, Hospitalized Patients with ENT on a Urine Culture: A Multicenter Evaluation. Open Forum Infectious Diseases, 2019, 6, S525-S526.	0.9	0
190	1485. Trends in Important-Resistant Gram-Negative (GN) and Gram-Positive (GP) Urine Bacterial Pathogens in Hospitalized Patients in the United States: A Multicenter Evaluation from 2013 to 2018. Open Forum Infectious Diseases, 2019, 6, S541-S541.	0.9	0
191	1601. Evaluation of Synergy with Î²-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA). Open Forum Infectious Diseases, 2019, 6, S584-S584.	0.9	0
192	2264. An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset (CO) â€œLow-Riskâ€•(LR) Complicated Intra-Abdominal Infections (cIAI) Across US Hospitals. Open Forum Infectious Diseases, 2019, 6, S775-S775.	0.9	0
193	2270. Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions?. Open Forum Infectious Diseases, 2019, 6, S777-S777.	0.9	0
194	164. Analysis of Adult, Hospitalized Patients With Carbapenem-resistant (CR) Gram-Negative Bloodstream Infections (GN-BSIs) due to Lactose Fermenters (LFs) and Non-lactose Fermenters (NLFs): Is There a Difference in Outcomes?. Open Forum Infectious Diseases, 2019, 6, S107-S107.	0.9	0
195	216. Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bloodstream Infections (GN-BSI). Open Forum Infectious Diseases, 2019, 6, S127-S127.	0.9	0
196	439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies. Open Forum Infectious Diseases, 2019, 6, S218-S218.	0.9	0
197	Impact of unit-specific metrics and prescribing tools on a family medicine ward. Infection Control and Hospital Epidemiology, 2020, 41, 1272-1278.	1.8	0
198	1623. Outcomes of Critically Ill Adults, Hospitalized Patients (Pts) with <i>Pseudomonas aeruginosa</i> (PSA) Hospital- and Ventilator-Associated Pneumonia (HAP/VAP) Who Received an Active Anti-Pseudomonal Î²-Lactam (ASPB): Does â€œSâ€•Equal Success in the Presence of Resistance to other ASPB?. Open Forum Infectious Diseases, 2020, 7, S804-S804.	0.9	0

#	ARTICLE	IF	CITATIONS
199	1683. Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals. Open Forum Infectious Diseases, 2020, 7, S825-S826.	0.9	0
200	1325. Things that go Bump in the Night: Combating Klebsiella pneumoniae co-producing New Delhi metallo-beta-lactamase (NDM) and Mobile Colistin Resistance (MCR). Open Forum Infectious Diseases, 2020, 7, S673-S673.	0.9	0
201	1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting. Open Forum Infectious Diseases, 2020, 7, S747-S748.	0.9	0
202	Panacea or oversimplification: Relating AUC and troughs. American Journal of Health-System Pharmacy, 2022, , .	1.0	0